Prescribing Patterns of Myeloid Growth Factors to Prevent Chemotherapy Related Febrile Neutropenia in Cancer Patients
Article Sidebar
Main Article Content
Abstract
Objective: To explores the patterns of myeloid growth factors (MGFs) usage in the prevention of chemotherapy (CMT) induced neutropenia. Method: This study was a retrospective chart review study. Data from 192 patients with 1,058 CMT cycles from 17 different cancer types were collected between January 1 and June 30, 2015. Risk assessment of febrile neutropenia (FN) was performed prior to every CMT cycle. The patterns of MGFs use for prophylaxis were recorded. Results: Overall, the consistency of the MGFs prophylaxis pattern with the Guideline was 63.04% of drug use. No CMT cycles were in the ‘Overuse’ group. Amongst the CMT regimens with FN high risk, 67.57% of the MGFs prophylaxis were consistent with the Guideline. Non-Hodgkin lymphoma was the most cancer type that received the MGFs prophylaxis. The majority of the MGFs prophylaxis in the CMT regimen with intermediate risk for FN and additional patient risk factors was in the ‘Underuse’ group (89.21%). Overall, MGFs prophylaxis was prescribed in 76 cycles (50 cycles for primary prophylaxis, and 26 cycles for secondary prophylaxis). Filgrastim was prescribed in all of cycles. The average of MGFs prophylaxis duration were 6.8±1.19 and 6.3±1.67 days for primary prophylaxis and secondary prophylaxis, respectively. Conclusion: Primary MGFs prophylaxis was more consistent with the Guideline than the secondary prophylaxis. Most of the CMT regimens with MGFs prophylaxis were classified as high FN risk CMT. Non-Hodgkin lymphoma and sarcoma with a higher reported FN rate, were the cancer types with the greatest adherence to the MGFs prophylaxis guideline.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Kobayashi SD, DeLeo FR. Role of neutrophils in innate immunity: a systems biology-level approach. Wiley Interdiscip Rev Syst Biol Med. 2009; 1: 309-33.
Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916-24.
Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258-66.
Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20:190-8.
Chindaprasirt J, Wanitpongpun C, Limpawattana P, Thepsuthammarat K, Sripakdee W, Sookprasert A, et al. Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. Asian Pac J Cancer Prev. 2013;14:1115-9.
Lyman GH, Dale DC. Hematopoietic growth factors in oncology. In: Rosen ST, editor: Cancer treatment and research: Springer; 2011. p.109-66.
Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-84.
Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008(4) :Cd003189.
Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007; 147: 400-11.
Wang L, Baser O, Kutikova L, Page JH, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23:3131-40.
Lee S, Knox A, Zeng IS, Coomarasamy C, Blacklock H, Issa S. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer. 2013;21:841-6.
Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, et al. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol. 2013;31:4283-9.
Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics. 2012;30:497-511.
Barnes G, Pathak A, Schwartzberg L. Pharmaco economics of granulocyte colony-stimulating factor: a critical review. Adv Ther. 2014;31:683-95.
National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology, myeloid growth factors [online]. 2015 [cited on Oct 26, 2015]. Available from: www.nccn.org/professional s/ physician_gls/pdf/myeloid_growth.pdf.
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33:3199–212.
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8-32.
Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, et al. Use of colony-stimulating factors with chemotherapy: opportuni- ties for cost savings and improved outcomes. J Natl Cancer Inst. 2011; 103: 979-82.
Waters GE, Corrigan P, Gatesman M, Smith TJ. Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpa- tient oncology clinic. J Oncol Pract. 2013;9:203-6.
Barnes G, Pathak A, Schwartzberg L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med. 2014;3:1477-84.
National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. [online]. 2010 [cited on Oct 26, 2015]. Available from: evs.nci.nih. gov/ftp1/CTCAE/CTCAE_4.03_2 010-06-14_Quick Reference_5x7.pdf.
McCune JS, Sullivan SD, Blough DK, Clarke L, McDermott C, Malin J, et al. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy. Pharmacotherapy. 2012;32:7-19.
Link H, Nietsch J, Kerkmann M, Ortner P. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a represen tative sample survey in Germany. Support Care Cancer. 2016; 24: 367-76.
Krzemieniecki K, Sevelda P, Erdkamp F, Smakal M, Schwenkglenks M, Puertas J, et al. Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice. Support Care Cancer. 2014;22:667-77.
Lyman GH, Kleiner JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. Cancer Treat Res. 2011;157:145-65.
McCall K, Johnston B. Treatment options in end-of-life care: the role of palliative chemotherapy. Int J Palliat Nurs. 2007;13:486-8.
Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014;90:190-9.
Weycker D, Barron R, Edelsberg J, Kartashov A, Legg J, Glass AG. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res. 2014;14:189.
Lin WT, Wen YW, Chien CR, Gau CS, Chiang SC, Hsiao FY. Suboptimal duration of granulocyte colony-stimulating factor use and chemotherapy-induced neutropenia in women diagnosed with breast cancer. Clin Ther. 2014;36:1287-94.
Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. J Oncol Pharm Pract. 2016;22:702-16.
Ip EJ, Lee-Ma A, Troxell LS, Chan J. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide. Am J Health Syst Pharm. 2008;65:1552-5.
J KH, D KO, Broyles JE, S CW. Impact of recom mended weight-based dosing of granulocyte-colony stimulating factors in acute leukemia and stem cell transplant patients. Support Care Cancer. 2017; 25: 1853-8.
Aoyagi T, Morii T, Tajima T, Yoshiyama A, Ichimura S. Analysis of the risk factors for febrile neutropenia in patients with bone and soft tissue sarcoma. Anticancer Res. 2015;35:2375-83.
Wojtukiewicz M, Chmielowska E, Filipczyk-Cisarz E, Krzemieniecki K, Lesniewski-Kmak K, Litwiniuk MM, et al. Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland. Contemp Oncol (Pozn). 2014;18:419-24.
